BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31392364)

  • 1. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
    Gardin A; Shakeri-Nejad K; Feller A; Huth F; Neelakantham S; Dumitras S
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1565-1574. PubMed ID: 31392364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
    Gardin A; Ufer M; Legangneux E; Rossato G; Jin Y; Su Z; Pal P; Li W; Shakeri-Nejad K
    Clin Pharmacokinet; 2019 Mar; 58(3):349-361. PubMed ID: 30088221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
    Gardin A; Gray C; Neelakantham S; Huth F; Davidson AM; Dumitras S; Legangneux E; Shakeri-Nejad K
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1593-1604. PubMed ID: 30105453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
    Gardin A; Dodman A; Kalluri S; Neelakantham S; Tan X; Legangneux E; Shakeri-Nejad K
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):54-65. PubMed ID: 27841151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Gardin A; Zaehringer A; Dodman A; Su Z; Legangneux E
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):41-53. PubMed ID: 27443658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.
    Shakeri-Nejad K; Gardin A; Gray C; Neelakantham S; Dumitras S; Legangneux E
    Clin Ther; 2020 Jan; 42(1):175-195. PubMed ID: 31926605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
    Huth F; Gardin A; Umehara K; He H
    Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
    Jin Y; Borell H; Gardin A; Ufer M; Huth F; Camenisch G
    Eur J Clin Pharmacol; 2018 Apr; 74(4):455-464. PubMed ID: 29273968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
    Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
    Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
    J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
    Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
    Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.
    Cox DS; Van Eyck L; Pawlak S; Beckerman B; Linn C; Ginman K; Thay Cha Y; LaBadie RR; Shi H; Damle B
    Br J Clin Pharmacol; 2023 Sep; 89(9):2867-2876. PubMed ID: 37184075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
    Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
    Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.